Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination

B‐cell depletion induced by anti‐cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccination, but effects on CD8 T‐cell responses are unknown. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Riise, Jon, Meyer, Saskia, Blaas, Isaac, Chopra, Adity, Tran, Trung T., Delic‐Sarac, Marina, Hestdalen, Malu Lian, Brodin, Ellen, Rustad, Even Holth, Dai, Ke‐Zheng, Vaage, John Torgils, Nissen‐Meyer, Lise Sofie Haug, Sund, Fredrik, Wader, Karin F., Bjornevik, Anne T., Meyer, Peter A., Nygaard, Gro O., König, Marton, Smeland, Sigbjørn, Lund‐Johansen, Fridtjof, Olweus, Johanna, Kolstad, Arne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Covid‐19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111866/
https://www.ncbi.nlm.nih.gov/pubmed/35254660
http://dx.doi.org/10.1111/bjh.18149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111866/
https://www.ncbi.nlm.nih.gov/pubmed/35254660
http://dx.doi.org/10.1111/bjh.18149

Ejemplares similares